Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation
-
Antonia Dastamani
Abstract
Background:
Sirolimus (mTOR inhibitor) is proven to be effective in children with congenital hyperinsulinism (CHI). Studies in animals suggest that sirolimus may have diabetogenic actions. However, its role in precipitating diabetes mellitus (DM) in children with CHI has not been reported.
Case presentation:
A 16-year-old female with CHI due to a dominant ABCC8 gene mutation was switched from diazoxide therapy to sirolimus, due to the hypertrichosis side effect of diazoxide. She developed facial cellulitis that was treated with clarithromycin and a month later, once the infection was resolved, she was found to have persistent hyperglycaemia, and was diagnosed with DM. She was unresponsive to oral sulfonylurea therapy and is currently managed with metformin. Her mother, who had the same ABCC8 mutation, developed DM at her 30s.
Conclusions:
Patients with dominant ABCC8 gene mutations are prone to DM in adulthood, but Sirolimus therapy might increase the risk of developing diabetes at an early age, as this case illustrates.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Senniappan S, Alexandrescu S, Tatevian N, Shah P, Arya V, et al. Sirolimus therapy in infants with severe hyperinsulinaemic hypoglycaemia. N Engl J Med 2014;370:1131–7.10.1056/NEJMoa1310967Search in Google Scholar
2. Méder Ü, Bokodi G, Balogh L, Körner A, Szabó M, et al. Severe hyperinsulinemic hypoglycemia in a neonate: response to sirolimus therapy. Pediatr 2015;136:1369–72.10.1542/peds.2014-4200Search in Google Scholar
3. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008;19:1411–8.10.1681/ASN.2007111202Search in Google Scholar PubMed
4. Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, Moya-Rull D, Ventura-Aguiar P, et al. mTOR inhibition: reduced insulin secretion and sensitivity in a rat model of metabolic syndrome. Transplant Direct 2016;2:65.10.1097/TXD.0000000000000576Search in Google Scholar
5. Pinney SE, MacMullen C, Becker S, Lin YW, Hanna C, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877–86.10.1172/JCI35414Search in Google Scholar PubMed
6. Kapoor RR, Flanagan SE, James CT, McKiernan J, Thomas AM, et al. Hyperinsulinaemic hypoglycaemia and diabetes mellitus due to dominant ABCC8/KCNJ11 mutations. Diabetologia 2011;54:2575–83.10.1007/s00125-011-2207-4Search in Google Scholar PubMed
7. Senniappan S, Shanti B, James C, Hussain K. Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and management. J Inherit Metab Dis 2012;35:589–601.10.1007/s10545-011-9441-2Search in Google Scholar PubMed
8. Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, et al. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301–7.10.1016/S0140-6736(03)12325-2Search in Google Scholar PubMed
9. Huopio H, Reimann F, Ashfield R, Komulainen J, Lenko H-L, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest 2000;106; 897–906.10.1172/JCI9804Search in Google Scholar PubMed PubMed Central
10. Thornton PS, MacMullen C, Ganguly A, Ruchelli E, Steinkrauss L, et al. Clinical and molecular characterization of a dominant form of congenital hyperinsulinism caused by a mutation in the high-affinity sulfonylurea receptor. Diabetes 2003;52:2403–10.10.2337/diabetes.52.9.2403Search in Google Scholar PubMed
11. Sankhala K, Mita A, Kelly K, Mahalingam D, Giles F, et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009;4:135–42.10.1007/s11523-009-0107-zSearch in Google Scholar PubMed
12. Di Paolo S, Teutonico A, Leogrande D, Capobianco C, Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? J Am Soc Nephrol 2006;17:2236–44.10.1681/ASN.2006030196Search in Google Scholar PubMed
13. Pavlakis M, Goldfarb-Rumyantzev AS. Diabetes after transplantation and sirolimus: what’s the connection? J Am Soc Nephrol 2008;19:1255–6.10.1681/ASN.2008050474Search in Google Scholar PubMed
14. Berg CE, Lavan BE, Rondinone CM. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. Biochem Biophys Res Commun 2002;293:1021–7.10.1016/S0006-291X(02)00333-9Search in Google Scholar PubMed
15. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008;57:945–95.10.2337/db07-0922Search in Google Scholar PubMed
16. Teutonico A, Schena P, Di Paolo S. Glucose metabolism in renal transplant recipients. Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005;16:3128–35.10.1681/ASN.2005050487Search in Google Scholar PubMed
17. Capone D, Palmiero G, Gentile A, Basile V, Fedetico S, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr Drug Metab 2007;8:379–81.10.2174/138920007780655405Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Mini Review
- Severe complications after initial management of hyperglycemic hyperosmolar syndrome and diabetic ketoacidosis with a standard diabetic ketoacidosis protocol
- Original Articles
- Markers influencing the presence of partial clinical remission in patients with newly diagnosed type 1 diabetes
- Oral health status of children with type 1 diabetes: a comparative study
- The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents
- High attainment of optimal nutritional and growth status observed among Greek pediatric cystic fibrosis patients: results from the GreeCF study
- Secular trends in height, weight and body mass index of primary school children in Turkey between 1993 and 2016
- Effects of 1-year growth hormone replacement therapy on thyroid volume and function of the children and adolescents with idiopathic growth hormone deficiency
- Thyroid hormone levels in late preterm, early term and term infants: a study with healthy neonates revealing reference values and factors affecting thyroid hormones
- Makorin ring finger 3 gene analysis in Koreans with familial precocious puberty
- Genetic analysis of fructose-1,6-bisphosphatase (FBPase) deficiency in nine consanguineous Pakistani families
- Reassessing the significance of the PAH c.158G>A (p.Arg53His) variant in patients with hyperphenylalaninemia
- Case Reports
- Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation
- Persistent de Quervain tenosynovitis induced by somatotropin treatment
- Early-onset severe obesity due to complete deletion of the leptin gene in a boy
- Congenital cataract with LSS gene mutations: a new case report
Articles in the same Issue
- Frontmatter
- Mini Review
- Severe complications after initial management of hyperglycemic hyperosmolar syndrome and diabetic ketoacidosis with a standard diabetic ketoacidosis protocol
- Original Articles
- Markers influencing the presence of partial clinical remission in patients with newly diagnosed type 1 diabetes
- Oral health status of children with type 1 diabetes: a comparative study
- The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents
- High attainment of optimal nutritional and growth status observed among Greek pediatric cystic fibrosis patients: results from the GreeCF study
- Secular trends in height, weight and body mass index of primary school children in Turkey between 1993 and 2016
- Effects of 1-year growth hormone replacement therapy on thyroid volume and function of the children and adolescents with idiopathic growth hormone deficiency
- Thyroid hormone levels in late preterm, early term and term infants: a study with healthy neonates revealing reference values and factors affecting thyroid hormones
- Makorin ring finger 3 gene analysis in Koreans with familial precocious puberty
- Genetic analysis of fructose-1,6-bisphosphatase (FBPase) deficiency in nine consanguineous Pakistani families
- Reassessing the significance of the PAH c.158G>A (p.Arg53His) variant in patients with hyperphenylalaninemia
- Case Reports
- Sirolimus precipitating diabetes mellitus in a patient with congenital hyperinsulinaemic hypoglycaemia due to autosomal dominant ABCC8 mutation
- Persistent de Quervain tenosynovitis induced by somatotropin treatment
- Early-onset severe obesity due to complete deletion of the leptin gene in a boy
- Congenital cataract with LSS gene mutations: a new case report
